Impairment of Neurogensis in the Olfactory Bulb of Transgenic Mice Overexpressing Human Wildtype Alpha Synuclein Under the Thy-1 Promoter
|
|
- Christian Little
- 5 years ago
- Views:
Transcription
1 Impairment of Neurogensis in the Olfactory Bulb of Transgenic Mice Overexpressing Human Wildtype Alpha Synuclein Under the Thy-1 Promoter Parkinson s disease (PD) is a progressive neurodegenerative disorder that impairs motor function. Patients with PD display motor symptoms including bradykinesia, akinesia, rigidity, resting tremor, and postural instability. In addition, recent studies have found early non-motor symptoms in patients with PD including olfactory impairments, gastrointestinal dysfunction, sleep disturbances, anxiety and depression. The genetically engineered alpha-synuclein overexpressing mice (ASO) under the Thy-1 promoter have high levels of alpha-synuclein and demonstrate distinctive proteinase K-resistant alphasynuclein inclusions throughout the brain including the thalamus, basal ganglia, cortex and olfactory bulb (Rockenstein et al., 2002). These mice demonstrate early and progressive motor impairments without the loss of nigrostriatal dopaminergic neurons at nine months of age (Fleming et al., 2004). The ASO mice under the Thy-1 promoter demonstrate olfactory impairments in olfactory tests and thus may present an early model of Parkinson s disease (Fleming et al., 2005). It has been documented that Parkinson s patients have impairments outside of the nigrostriatal pathway. One area that can be affected is the olfactory senses. The olfactory neurons are renewed throughout life: the neurons originate from the subventricular zone (SVZ) and then migrate along the rostral migratory stream (RMS), which are surrounded by olfactory ensheathing glia, and eventually reach the olfactory bulb (Gritti et al., 2002). Recent studies have shown that the ASO mice under the PDGFß promoter have impairments in neurogenesis of the olfactory bulb and hippocampus, presenting a mouse model of PD with impairments outside the of the nigrostriatal pathway (Winner et al., 2004). The goal of the project outlined in this proposal is to investigate whether animals exhibiting an accumulation of alpha-synuclein in the olfactory bulb demonstrate impairments in the olfactory senses. This study can provide a better understanding of early symptoms of Parkinson s disease. It will also provide better criteria for testing and diagnosing the earlier stages of Parkinson s disease and may allow for early therapeutic interventions. A. Specific Aims: This project aims to gain an understanding of the relationship between alphasynuclein accumulation in the olfactory bulb and olfactory impairments. The main hypothesis is that alpha-synuclein accumulation in olfactory bulb causes the olfactory impairments. The alpha-synuclein accumulation in the olfactory bulb may cause a disruption in neurogenesis and cause the olfactory impairments. Hypothesis 1: To test whether mice overexpression of alpha-synuclein under the Thy-1 promoter exhibit an impairment of neurogenesis in the olfactory bulb. Hypothesis 2: To test in the alpha-synuclein over-expressing mice under the Thy-1 promoter, whether olfactory impairments are correlated with a perturbance in the neurogenesis of the olfactory bulb. Hypothesis 1 will be tested by quantifying the number of bromodeoxyuridine (BrdU) positive cells in the olfactory bulb of the ASO and wild type (WT) littermate controls using the techniques of immunohistochemistry and stereology. In addition, hypothesis 1 will be addressed by the quantification of the following double-label immunohistochemical experiments: BrdU and Tunnel, BrdU and alpha-synuclein, BrdU
2 and Neu-N, BrdU and tyrosine hydroxylase (TH). Hypothesis 2 will be will be addressed by testing olfactory impairments with olfactory tests including the block test, habituationdishabituation test and by correlating the quantification of the BrdU-positive cells and α- synuclein accumulation in the ASO mice compared to WT. B. Background and Significance Parkinson s disease (PD) is a neurological disorder characterized by the degeneration of dopaminergic neurons in the nigrostrial pathway. The accumulation of alpha-synuclein in the brain and peripheral tissues results in the formation of Lewy bodies, a hallmark of PD. (Braak et al., 2004) Patients often suffer a combination of motor symptoms including resting tremor, rigidity, bradykinesia and postural instability. By the time patients are diagnosed with PD, 80% of their dopaminergic neurons in the substantia nigra pars compacta have degenerated causing devastating effects on their motor function (DeKosky et al., 2003). Recent studies have shown that prior to the motor deficits typically indicative of PD, a number of other symptoms develop, including olfactory impairments, gastrointestinal dysfunction, sleep disturbances, anxiety and depression. The staging of pathology in sporadic PD demonstrates that lesions in the olfactory bulb and cortex develop in the early stages of PD, whereas the nigrostrial cell loss occurs in the later stages of PD (Braak et al., 2004). This provides strong evidence for the value of studying olfaction in PD. Transgenic mice that overexpress alpha-synuclein (ASO) under the Thy-1 promoter demonstrate high levels of alpha-synuclein inclusions throughout the brain including the olfactory bulb, thalamus, basal ganglia and cortex (Rockenstein et al., 2002). Male ASO mice at 3-4 months under the Thy-1 promoter demonstrate significant (p< 0.01) olfactory impairments with olfactory tests such as the novel olfaction capacity test (figure 1) and the habituation/dishabituation test (figure 2) (Fleming et al., 2005). The mechanism of the olfactory impairments in the PD is not well understood. The olfactory bulb has neurogenesis throughout life. The olfactory neurons originate from the subventricular zone (SVZ) and then migrate along the rostral migratory stream (RMS), surrounded by olfactory ensheathing glia, eventually reaching the olfactory bulb (Gritti et al., 2002). Renewal of olfactory neurons is essential for proper olfactory detection and discrimination. It has been documented that ASO mice under the PDGFß promoter have impairments in neurogenesis of the olfactory bulb (Winner et al., 2004). The ASO mice under the Thy-1 promoter exhibit numerous alpha-synuclein inclusions in the olfactory bulb and display demonstrable olfaction impairments. (Rockenstein et al., 2002; Fleming et al., 2005). It is critical to test whether alpha synuclein aggregates cause a disruption of neurogenesis in the olfactory bulb in the ASO mice. This would allow for a better understanding of the early symptoms of PD and thereby provide for possible early detection and early intervention in humans.
3 C. Preliminary Data Time (seconds) Block Test Trial 7 at 3 Months Blocks 1, 2, 3 and 5 * WT ASO Figure 1: At 3 months, WT and ASO were tested for olfactory capacity with the block test (Spinetta et al., 2005). On trial 7, the mice were exposed to blocks 1, 2, 3 and 5 (novel block from another animal s cage) and video taped for 30 seconds. The time the animal spent in olfactory investigation was measured. WT (n=16) compared to ASO (n=7) spent significant ( p < 0.005) more time in olfactory investigation of block 5. In addition, WT spent significant (*p < 0.001) more time in olfactory investigation with block 5 compared to blocks 1,2 and 3. Time (seconds) Banana and Lemon Pair at 3 Months Trial WT ASO Figure 2: At 3 months, the habituationdishabituation test (Bielsky et al., 2004) tested for olfactory discrimination of innocuous scent pairs in different scent categories. Trials 1-7 were recorded and video taped for 30 seconds per trial. The time the animal spent in olfactory investigation was measured for each trial. For trials 1-6 the animal was exposed to the first scent (banana) and was introduced the novel scent on trial 7 (lemon). ASO (n=7) and WT (n=16) habituate the first scent (p < 0.05). While the ASO spend less time in olfactory investigation there is no significant difference when compared to WT. D. Experimental Design This is a two-part study to evaluate the olfactory impairments in the ASO mice. First, the animals will be tested using of olfactory tests such as the block test and habituation-dishabituation test. The second part of the study will analyze the olfactory bulb for neurogenesis, neuronal survival, neuronal differentiation and for the accumulation of alpha-synuclein in ASO mice compared to WT mice. Animals Human alpha-synuclein overexpressing transgenic mice under the Thy-1 promoter (ASO) and wild type (WT) litter mate controls will be tested (Rockenstein et al., 2002). There will be two time groups for olfaction testing. Forty male mice will be tested for the olfactory function; ASO (n=10) and WT controls (n=10) at 3-4 months of age and ASO (n=10) and (WT) controls (n=10) at 9 months of age.
4 Olfaction Tests Olfaction Capacity Test / Block Test Animals are individually housed with five wooden blocks (2.5 cm 3 ) numbered 1-5 placed in each animal s cage for at least one week prior to testing. On the day of the testing, animals habituate to the room for one hour of low light. During this time, all five blocks and some bedding are removed from each cage and placed in a plastic bag labeled with the animal s identification. At the time of testing blocks 1-4 from the animal s cage are placed in the middle of the cage. The mouse is then videotaped for 30 seconds. The test is repeated for a total of six exposures to blocks 1-4. On the seventh trial, block 4 is replaced with block 5 from another mouse s cage; thus blocks 1, 2, and 3 from its own cage and the novel block 5 are placed in the animal s cage. If olfaction function is intact, the mouse should detect the novel odor and therefore spend more time sniffing the novel block. The animals are recorded on a video camera for 30 seconds and the time spent in olfactory investigation is measured and calculated by a rater blind to genotype (Spinetta et al., 2005). Habituation / Dishabituation Test Similarly to the block test, animals are individually housed. An unscented tissue cartridge is placed into each animal s cage for one week prior to testing in order for animals to habituate directly to the stimulus. On the day of testing, animals are transferred into the testing room and allowed to adjust to the low light for one hour. During testing the animals receive a total of seven exposure trials. For each of the first six trials animals are exposed to the same scent (banana) to habituate to that scent. On the seventh trial, animals are exposed to a novel scented cartridge (lemon). The animals are recorded on a video camera for 30 seconds and the time spent in olfactory investigation is measured and calculated by a rater blind to genotype (Bielsky et al., 2004). Tissue cartridges (Omnisette tissue cartridge, Fisher Scientific) are loaded with a cotton ball injected with the various odors. Every other day, paired scents are tested in the following order: banana and lemon, coconut and anise, pine and cinnamon, lemon and lime, lemon and orange, and lime and orange. Bromodeoxyuridine (BrdU) Injections After the olfaction test, the two groups of mice at 4 and 9 months receive five injections of BrdU every eight hours over a forty-hour period (Gotts et al., 2002, Winner et al., 2004). BrdU labels newly-born cells by labeling DNA synthesis in the S phase of the cell cycle (Bauer et al., 2005). The animals are then sacrificed one month after BrdU injections to study neurogenesis differentiation in the olfactory bulb. Immunohistochemistry Neurogensis and cell survival Double immunohistochemistry of BrdU with Tunnel (a cell death marker) effectively permits identification of those newly-born cells in the olfactory bulb that do not survive. The number of BrdU positive cells and the number of BrdU and Tunnel double labeled cells are stereologically quantified. This addresses the important question of how many newly born cells survive in the olfactory bulb of ASO as compared to WT so that actual genesis of the olfactory bulb is quantified.
5 Neurogensis and alpha-synuclein accumulation A double immunohistochemical label of BrdU and alpha-synuclein, which labels alphasynuclein aggregates will be stereologically quantified in the olfactory bulb of the ASO and WT mice. This will address whether alpha-synuclein aggregates disrupt neurogenesis in the olfactory bulb. Neurogensis and neuronal differentiation Double immunohistochemical label of the BrdU and Neu-N, which is a neuronal marker, would determine the number of BrdU positive cells that turn into neurons. A stereological analysis of the double labeled Neu-N and BrdU positive cells will be compared in olfactory bulb of the ASO to WT mice. Double immunohistochemical label of the BrdU and tyrosine hydroxylase (TH), which labels dopaminergic cells would determine the number of BrdU-positive cells that turn into dopaminergic neurons. A stereological analysis of the double-labeled TH and BrdU positive cells in the olfactory bulb will be compared in the ASO to WT mice. Stereology The unbiased stereology will be performed with the use of the Stereoinvestigator software (Microbright Field Inc.). An optical dissector will be designed to allow for a systematic, random counting procedure and the volume will be determined by tracing the region of interest. Every 5 th section ( 200 µm interval) of the left hemisphere of each animal will be processed for immunohistochemistry. The granule cell layer of the olfactory bulb labeled with BrdU, NeuN and Tunnel positive cells will be counted with a counting frame of 60µm x 60µm and a 200µm x 200µm counting grid. The TH-positive cells will be counted in the glomerular layer of the olfactory bulb with a 20µm x 20µm counting frame and a 100µm x 100µm counting grid (Winner et al., 2004). Limitations Other brain regions such as the olfactory cortex and frontal cortex could be perturbed, causing the olfactory impairments. Thus, it would be helpful to quantify of the neurons in the olfactory cortex and in frontal cortex to determine whether those regions are involved in the olfactory impairments. Another possible explanation could be there is a disruption in the cellular functionality. The olfactory impairments could be due to a disruption in the connectivity of the neurons in the olfactory bulb. In this case, it would be important to test the functional connectivity of the cellular layers in the olfactory bulb and test whether the projections to the olfactory cortex are intact. In addition, the olfactory cortex could be altered and may cause the olfactory impairments. Thus, the quantification of the neurons in the olfactory cortex would be another area to examine to establish the regions involved in the olfactory impairments. Future Directions This study will provide evidence for early staging of PD. This study has relevant clinical application for detecting the early stages of PD, which provides patients with the opportunity to use early therapeutic interventions. In addition, it would be important to study the migration of newly born cells from the SVZ to the olfactory bulb and to analyze the pathway for possible mechanisms of interference. Also, it is valuable to test ASO mice for the additional early non-motor symptoms including gastrointestinal dysfunction, sleep disturbances, anxiety and depression. This could allow for the development of better criteria to test for the early symptoms in Parkinson s disease.
6 E. References: Bauer S and Patterson PH. The cell cycle apoptosis connection revisited in the adult brain. J. Cell Biol., Nov 2005; 171: Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology Mar;29(3): Braak H, Ghebremedhin E, Röb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson s disease-related pathology. Cell and Tissue Research Oct; 318(1): DeKosky ST and Marek K. Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders. (2003). Science 302: Fernagut PO, Chesselet MF. Alpha-synuclein and transgenic mouse models. Neurobiol Dis Nov;17(2): Review. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E,. Levine MS, and Chesselet MF. Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human Synuclein. J. Neurosci. 24: ; doi: /jneurosci Fleming SM, Fernagut PO, Tetreault NA, Rockenstein E, Masliah E, Levine MS, Chesselet MF (2005) Non-Motor Impairments In Transgenic Mice Overexpressing Human Wild-Type α-synuclein. Soc. Neurosci. Abstract. Gotts JE, Chesselet MF. Migration and fate of newly born cells after focal cortical ischemia in adult rats. J Neurosci. Res Apr 15;80(2): Gritti A, Bonfanti L, Doetsch L, Caille I, Alvarez-Buylla A, Lim DA, Galli R, Garcia Verdugo JM, Herrera DG, and Vescovi AL. Multipotent Neural Stem Cells Reside into the Rostral Extension and Olfactory Bulb of Adult Rodents. J. Neurosci., Jan 2002; 22: Gundersen H.J.G. Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R Thompson. J Microsc. 1986; 143(Pt 1): Rockenstein E,Mallory M,Hashimoto M,Song D,Shults CW,Lang I,Masliah E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res Jun 1;68(5): Spinetta MJ, Woodlee MT, Hester NW, Heymann JC, Feinberg LM, Rajagopalan KN, Lichtenwalner R, Parent J, Schallert T. A Simple and Sensitive Odor Recognition Test for Rats and Mice Detects Retrograde Amnisa Caused by Ethanol or Other Drugs that Interfere with Memory Cosolidation. Program No Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, Online.
7 Winner B, Lie DC, Rockenstein E, Aigner R, Aigner L, Masliah E, Kuhn HG, Winkler J. Human wild-type alpha-synuclein impairs neurogenesis. J Neuropathology Experimental Neurology 2004 Nov;63(11):
NIH Public Access Author Manuscript Parkinsonism Relat Disord. Author manuscript; available in PMC 2009 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Parkinsonism Relat Disord. 2008 ; 14(Suppl 2): S84 S87. doi:10.1016/j.parkreldis.2008.04.004. Strengths and Limitations of Genetic
More informationModeling Parkinson s disease: systems to test gene-environment interactions
Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)
More informationThe Parkinson s You Can t See
The Parkinson s You Can t See We principally see the motor phenomena of Parkinson's disease, but is there an early stage without visible features? Might this provide a window for disease-modifying therapy?
More informationLecture 42: Final Review. Martin Wessendorf, Ph.D.
Lecture 42: Final Review Martin Wessendorf, Ph.D. Lecture 33 cortex Heilbronner 5 lobes of the cortex Lateral view (left side) Mid-saggital view (right side) Cellular organization of cortex White matter
More informationNeuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide
Neuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide Bruce H. Morimoto, Ph.D. Executive Director, Applied Translational Medicine Microtubules Microtubules essential for neuronal
More informationNew Approach to Parkinson s Disease: Synuclein Immunotherapy
RB2014 Conference August 22, 2014 New Approach to Parkinson s Disease: Synuclein Immunotherapy Dale Schenk, PhD President and CEO Prothena Corporation plc Primary Motor and Non-Motor Symptoms of Parkinson
More informationA Progressive Mouse Model of Parkinson s Disease: The Thy1-aSyn ( Line 61 ) Mice
Neurotherapeutics (2012) 9:297 314 DOI 10.1007/s13311-012-0104-2 REVIEW A Progressive Mouse Model of Parkinson s Disease: The Thy1-aSyn ( Line 61 ) Mice Marie-Francoise Chesselet & Franziska Richter &
More informationNeural stem cells and the neurobiology of ageing. Chen Siyun 1, Dawe G.S. 2
ABSTRACT Neural stem cells and the neurobiology of ageing Chen Siyun 1, Dawe G.S. 2 Department of Physics, Faculty of Science, National University of Singapore 10 Kent Ridge Road, Singapore 117546 The
More informationSeafood Contaminants causing Foodborne Diseases
Seafood Contaminants causing Foodborne Diseases Bacteria and Viruses Vibrio species Viruses: Norwalk-like (NLV) and Hepatitis A (HAV) Industrial Compounds Mercury Polyclorinated biphenyls (PCBs) Natural
More informationVol 6, Iss 9, May 5, 2016
Olfactory Recognition Memory Test in Mice Stephanie A. Jacobs 1*, Fengying Huang 1, Joe Z. Tsien 1 and Wei Wei 2* 1 Department of Neurology, Brain and Behavior Discovery Institute, Medical College of Georgia,
More informationKinematic Modeling in Parkinson s Disease
Kinematic Modeling in Parkinson s Disease Alexander Hui Department of Bioengineering University of California, San Diego La Jolla, CA 92093 alexhui@ucsd.edu Abstract Parkinson s disease is a slowly progressing
More informationLecture XIII. Brain Diseases I - Parkinsonism! Brain Diseases I!
Lecture XIII. Brain Diseases I - Parkinsonism! Bio 3411! Wednesday!! Lecture XIII. Brain Diseases - I.! 1! Brain Diseases I! NEUROSCIENCE 5 th ed! Page!!Figure!!Feature! 408 18.9 A!!Substantia Nigra in
More informationParkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.
Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationInvestigating molecular mechanisms of progression of Parkinson s Disease in human brain
Investigating molecular mechanisms of progression of Parkinson s Disease in human brain Murray ; C.E., Pressey ; S.N., Heywood 2 ; W.E., Hargreaves 3 ; I.P., Neergheen 3 ; V., Wauters ; S., Palkovits 4
More informationAssessing mouse behaviors: Modeling pediatric traumatic brain injury
Assessing mouse behaviors: Modeling pediatric traumatic brain injury Bridgette Semple Ph.D. Postdoctoral Fellow, Noble Laboratory Department of Neurological Surgery, UCSF Pediatric Traumatic Brain Injury
More informationPrion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice
Prion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice Nolwen L. Rey, PhD Patrik Brundin s Laboratory, Van Andel Research Institute Grand Rapids, Michigan, USA 15th Annual
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationSupplementary Materials for. c-abl Activation Plays a Role in α-synucleinopathy Induced Neurodegeneration
Supplementary Materials for c-abl Activation Plays a Role in α-synucleinopathy Induced Neurodegeneration Saurav Brahmachari, Preston Ge, Su Hyun Lee, Donghoon Kim, Senthilkumar S. Karuppagounder, Manoj
More informationRasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease. Petit, Géraldine; Berkovich, Elijahu; Hickery, Mark; Kallunki, Pekka; Fog, Karina; Fitzer-Attas, Cheryl;
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationCheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy
Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:
More informationNeurogenesis in Adult Central Nervous System: Death of a Dogma
Aristotle University of Thessaloniki, Greece, Nov. 2007 Neurogenesis in Adult Central Nervous System: Death of a Dogma Anton B. Tonchev Division of Cell Biology, Varna University of Medicine, Bulgaria
More informationPrss56, a novel marker of adult neurogenesis in the mouse brain. - Supplemental Figures 1 to 5- Brain Structure and Function
Prss56, a novel marker of adult neurogenesis in the mouse brain - Supplemental Figures 1 to 5- Brain Structure and Function Alexandre Jourdon 1,2, Aurélie Gresset 1, Nathalie Spassky 1, Patrick Charnay
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationAre Both Embryonic Migratory Pathways Preserved in the Adult Brain Cerebral Cortex?
Prague Medical Report / Vol. 107 (2006) No. 1, p. 71 80 71) Are Both Embryonic Migratory Pathways Preserved in the Adult Brain Cerebral Cortex? Šimonová Z., Dutt J. Department of Neuroscience of the Institute
More informationBasal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota
Basal Ganglia Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Graduate School Discussion Wednesday, Nov 1, 11:00am MoosT 2-690 with Paul Mermelstein (invite your friends)
More informationMAXIMIZING FUNCTION IN PARKINSON S DISEASE
1 MAXIMIZING FUNCTION IN PARKINSON S DISEASE September 13, 2016 End Falls This Falls Conference Jan Goldstein Elman One Step Ahead Mobility Toronto, Ontario Outline An overview of Parkinson s disease (PD):
More informationThe Marmoset Monkey as Model for Neurological Disorders
The Marmoset Monkey as Model for Neurological Disorders Jan Langermans and Ingrid Philippens From Laboratory to Clinic Disease models neuroscience: Parkinson, Sleep, Stress, Alzheimer, MS MS Models: rhmog
More informationErbB4 migrazione I parte. 3- ErbB4- NRG1
ErbB4 migrazione I parte 3- ErbB4- NRG1 1 In rodent brains postnatal neuronal migration is evident in three main areas: the cerebellum (CB), the hippocampus (Hipp) and the rostral migratory stream (RMS).
More informationBasal Ganglia General Info
Basal Ganglia General Info Neural clusters in peripheral nervous system are ganglia. In the central nervous system, they are called nuclei. Should be called Basal Nuclei but usually called Basal Ganglia.
More informationFDG-PET e parkinsonismi
Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism
More informationChapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.
Chapter 8 Parkinsonism M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Definition of Parkinson s Disease Parkinson's disease is a progressive, neurodegenerative disease
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationStrategies for Neurorestoration: Growth Factors
Strategies for Neurorestoration: Growth Factors Elena Posse de Chaves, PhD 928-MSB Phone: 492-5966 Email: elena.chaves@ualberta.ca Treatment of Neurodegenerative Diseases Most neurodegenerative diseases
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationBasal ganglia Sujata Sofat, class of 2009
Basal ganglia Sujata Sofat, class of 2009 Basal ganglia Objectives Describe the function of the Basal Ganglia in movement Define the BG components and their locations Describe the motor loop of the BG
More informationmir-7a regulation of Pax6 in neural stem cells controls the spatial origin of forebrain dopaminergic neurons
Supplemental Material mir-7a regulation of Pax6 in neural stem cells controls the spatial origin of forebrain dopaminergic neurons Antoine de Chevigny, Nathalie Coré, Philipp Follert, Marion Gaudin, Pascal
More informationWhat goes wrong with balance in Parkinson s Disease? Fay B Horak, PhD, PT Professor of Neurology Oregon Health and Science. CoM
What goes wrong with balance in Parkinson s Disease? Fay B Horak, PhD, PT Professor of Neurology Oregon Health and Science CoM CoM Course Objectives Understand different types of balance systems affected
More informationErbB4 migrazione II parte
ErbB4 migrazione II parte Control SVZ cells prefer to migrate on the NRG1 type III substrate the substrate preference of the neuroblasts migrating out of the SVZ explant was evaluated SVZ cells had a strong
More informationSupplementary Figure 1. Nature Neuroscience: doi: /nn.4547
Supplementary Figure 1 Characterization of the Microfetti mouse model. (a) Gating strategy for 8-color flow analysis of peripheral Ly-6C + monocytes from Microfetti mice 5-7 days after TAM treatment. Living
More informationBasal Ganglia George R. Leichnetz, Ph.D.
Basal Ganglia George R. Leichnetz, Ph.D. OBJECTIVES 1. To understand the brain structures which constitute the basal ganglia, and their interconnections 2. To understand the consequences (clinical manifestations)
More informationANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE
ANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE 21 February 217 MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission To accelerate the development
More informationANNOTATED BIBLIOGRAPHY
ANNOTATED BIBLIOGRAPHY Source 1: Akpinar, B. (2005). The role of the sense of smell in learning and the effect of aroma in cognitive learning. Pakistan Journal of Social Science, 3(7), Retrieved from http://docsdrive.com/
More informationExtrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010
Extrapyramidal Motor System Basal Ganglia or Striatum Descending extrapyramidal paths receive input from other parts of motor system: From the cerebellum From the basal ganglia or corpus striatum Caudate
More informationCortical contusion injury disrupts olfactory bulb neurogenesis in adult mice
Radomski et al. BMC Neuroscience 2013, 14:142 RESEARCH ARTICLE Open Access Cortical contusion injury disrupts olfactory bulb neurogenesis in adult mice Kryslaine L Radomski, Qiong Zhou, Kevin J Yi and
More informationCell Migration II: CNS Cell Migration. Steven McLoon Department of Neuroscience University of Minnesota
Cell Migration II: CNS Cell Migration Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Coffee Hour Wednesday (Oct 18) 9:00-10:00am Surdyk s Café in Northrop Auditorium Stop
More informationThe Effects of Chemotherapy on Cognitive Behavior and Neurogenesis in an Animal Model of Pre- and Post- Menopausal Females
The Effects of Chemotherapy on Cognitive Behavior and Neurogenesis in an Animal Model of Pre- and Post- Menopausal Females Samantha Pavlock (Medical Student) Pradeep Bhide and Deirdre McCarthy (Faculty
More informationBiomedical Technology Research Center 2011 Workshop San Francisco, CA
Diffusion Tensor Imaging: Parkinson s Disease and Atypical Parkinsonism David E. Vaillancourt court1@uic.edu Associate Professor at UIC Departments t of Kinesiology i and Nutrition, Bioengineering, and
More informationA. General features of the basal ganglia, one of our 3 major motor control centers:
Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. March 1, 2012 THE BASAL GANGLIA Objectives: 1. What are the main
More informationDamage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.
Lecture 20 - Basal Ganglia Basal Ganglia (Nolte 5 th Ed pp 464) Damage to the basal ganglia produces involuntary movements. Although the basal ganglia do not influence LMN directly (to cause this involuntary
More informationWhy is neuroplasticity needed? Session 301: Rerouting Neural Pathways: Advancing Pediatric Function Through Neuroplasticity Karen Pryor PhD, PT, DPT
To comply with professional boards/associations standards: I declare that I (or my family) do not have a financial relationship in any amount, occurring in the last 12 months with a commercial interest
More informationNature Neuroscience: doi: /nn Supplementary Figure 1. Large-scale calcium imaging in vivo.
Supplementary Figure 1 Large-scale calcium imaging in vivo. (a) Schematic illustration of the in vivo camera imaging set-up for large-scale calcium imaging. (b) High-magnification two-photon image from
More informationFOUNDATION OF UNDERSTANDING PARKINSON S DISEASE
FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE DEE SILVER M.D MOVEMENT DISORDER SPECIALIST MEDICAL DIRECTOR -- PARKINSON ASSOCIATION OF SAN DIEGO 1980 TO PRESENT SCRIPPS MEMORIAL HOSPITAL, LA JOLLA CA.
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationVisualization and simulated animations of pathology and symptoms of Parkinson s disease
Visualization and simulated animations of pathology and symptoms of Parkinson s disease Prof. Yifan HAN Email: bctycan@ust.hk 1. Introduction 2. Biochemistry of Parkinson s disease 3. Course Design 4.
More informationVL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements
BASAL GANGLIA Chris Cohan, Ph.D. Dept. of Pathology/Anat Sci University at Buffalo I) Overview How do Basal Ganglia affect movement Basal ganglia enhance cortical motor activity and facilitate movement.
More informationA. General features of the basal ganglia, one of our 3 major motor control centers:
Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. April 22, 2010 THE BASAL GANGLIA Objectives: 1. What are the
More informationNeuroplasticity:. Happens in at least 3 ways: - - -
BRAIN PLASTICITY Neuroplasticity:. Happens in at least 3 ways: - - - Recently, it was found that new neurons and glial cells are born in specific brain regions - reorganization. Brain plasticity occurs
More informationSOM Husse et al. Supplementary online material. Synaptotagmin10-Cre, a driver to disrupt clock genes in the SCN
SOM Husse et al. Supplementary online material Synaptotagmin10-Cre, a driver to disrupt clock genes in the SCN Jana Husse, Xunlei Zhou, Anton Shostak, Henrik Oster and Gregor Eichele SOM Husse et al.,
More informationBRAIN PLASTICITY. Neuroplasticity:. Happens in at least 3 ways: - - -
BRAIN PLASTICITY Neuroplasticity:. Happens in at least 3 ways: - - - Recently, it was found that new neurons and glial cells are born in specific brain regions - reorganization. Brain plasticity occurs
More informationMilestones of neuronal development in the adult hippocampus
Milestones of neuronal development in the adult hippocampus Gerd Kempermann 1,2, Sebastian Jessberger 2, Barbara Steiner 2 and Golo Kronenberg 1,3 1 Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch,
More informationDr. Farah Nabil Abbas. MBChB, MSc, PhD
Dr. Farah Nabil Abbas MBChB, MSc, PhD The Basal Ganglia *Functions in association with motor cortex and corticospinal pathways. *Regarded as accessory motor system besides cerebellum. *Receive most of
More informationYasuhiko Matsumori, Jialing Liu, Philip R. Weinstein, Takamasa Kayama ABSTRACT
Yamagata Med J 2003 21 2) 171-175 Yasuhiko Matsumori, Jialing Liu, Philip R. Weinstein, Takamasa Kayama Department of Neurosurgery, Yamagata University School of Medicine, Yamagata, Japan Department of
More informationSupplementary Figure 1
Supplementary Figure 1 Genetic labeling of microglia Male and female 2-3 month-old CreERT2;R26-tdTomato mice or CreERT2;R26-tdTomato;Iba1-eGFP transgenic mice were treated with 1x, 2x (48 h apart), or
More informationSupplementary Fig. 1: TBR2+ cells in different brain regions.
Hip SVZ OB Cere Hypo Supplementary Fig. 1: TBR2 + cells in different brain regions. Three weeks after the last tamoxifen injection, TBR2 immunostaining images reveal a large reduction of TBR2 + cells in
More informationImpact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson s Disease
Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson s Disease FABIO G. TEIXEIRA,MIGUEL M.CARVALHO KRISHNA M. PANCHALINGAM ANA J.RODRIGUES
More informationParkinsons Disease & Movement Disorder Aug 11-13, Frankfurt l Dr. Geeta Shroff
USE OF HUMAN EMBRYONIC STEM CELLS IN THE TREATMENT OF PARKINSON S DISEASE Dr. Geeta Shroff Founder and Medical Director, Nutech Mediworld CONDITIONS TREATED Spinal Cord Injury Cell Culture Technology Diabetes
More informationMultiple memory trace theory Duncan, 1949
Neurobiology of Learning and Memory Prof. Stephan Anagnostaras Lecture 5: Memory Consolidation Multiple memory trace theory Duncan, 1949 McGaugh, 2 Squire: retention of TV shows after ECS At least 2 kinds
More informationCSE511 Brain & Memory Modeling Lect 22,24,25: Memory Systems
CSE511 Brain & Memory Modeling Lect 22,24,25: Memory Systems Compare Chap 31 of Purves et al., 5e Chap 24 of Bear et al., 3e Larry Wittie Computer Science, StonyBrook University http://www.cs.sunysb.edu/~cse511
More informationExam 2 PSYC Fall (2 points) Match a brain structure that is located closest to the following portions of the ventricular system
Exam 2 PSYC 2022 Fall 1998 (2 points) What 2 nuclei are collectively called the striatum? (2 points) Match a brain structure that is located closest to the following portions of the ventricular system
More informationCOGNITIVE SCIENCE 107A. Motor Systems: Basal Ganglia. Jaime A. Pineda, Ph.D.
COGNITIVE SCIENCE 107A Motor Systems: Basal Ganglia Jaime A. Pineda, Ph.D. Two major descending s Pyramidal vs. extrapyramidal Motor cortex Pyramidal system Pathway for voluntary movement Most fibers originate
More informationTHE EXPRESSION OF INOS IN MOUSE EXPERIMENTAL MODEL POINTS TO INFLAMMATORY CONDITIONS ASSOCIATED WITH PARKINSON S DISEASE
THE EXPRESSION OF INOS IN MOUSE EXPERIMENTAL MODEL POINTS TO INFLAMMATORY CONDITIONS ASSOCIATED WITH PARKINSON S DISEASE Fatima Laiche Noureddine Djebli Mostaganem University, Algeria Abstract Parkinson
More informationShift 1, 8 July 2018, 09:30-13:00
Shift 1, 8 July 2018, 09:30-13:00 CNS patterning A001-A014 Stem cells: basic biology and postnatal neurogenesis - part I Development of neural systems: Molecular and genetic characterisationa Epigenetic
More informationGene co-expression networks in the mouse, monkey, and human brain July 16, Jeremy Miller Scientist I
Gene co-expression networks in the mouse, monkey, and human brain July 16, 2013 Jeremy Miller Scientist I jeremym@alleninstitute.org Outline 1. Brief introduction to previous WGCNA studies in brain 2.
More informationMaking Things Happen 2: Motor Disorders
Making Things Happen 2: Motor Disorders How Your Brain Works Prof. Jan Schnupp wschnupp@cityu.edu.hk HowYourBrainWorks.net On the Menu in This Lecture In the previous lecture we saw how motor cortex and
More informationUsing Sources in the GDP
Using Sources in the GDP The following are five examples of sources that you may encounter while working on your GDP project. The information contained in each of these sources (shown by screen shot) was
More informationCell Migration II: CNS Cell Migration. Steven McLoon Department of Neuroscience University of Minnesota
Cell Migration II: CNS Cell Migration Steven McLoon Department of Neuroscience University of Minnesota 1 Hey! The major concepts discussed relative to neural crest cell migration apply to cell migration
More informationPostural instability Hypokinesia Rigidity Tremor Forward flexed posture. pain million people 50+ years old 10 most populated countries
4.1-4.6 million people 50+ years old 10 most populated countries Cyndi Robinson, PT, PhD University of Washington Seattle, Washington, USA Progressive neurodegenerative disorder Selective neuronal loss
More information2/5/2015. Sensitive: Discriminative: Simple Inexpensive. Example of a good biomarker: blood tests, CSF test but they are not discriminative for PD
Jeffrey H. Kordower, Ph.D.. Department of Neurological Sciences Rush University Medical Center Sensitive: Discriminative: Simple Inexpensive Example of a good biomarker: blood tests, CSF test but they
More informationChapter 8. Control of movement
Chapter 8 Control of movement 1st Type: Skeletal Muscle Skeletal Muscle: Ones that moves us Muscles contract, limb flex Flexion: a movement of a limb that tends to bend its joints, contraction of a flexor
More informationCURRICULUM VITAE. Jonathan Dickerson B.S. Biology, Wilmington College.
CURRICULUM VITAE Jonathan Dickerson Education: 1999-2003 B.S. Biology, Wilmington College. 2004-2010 Ph.D., Neuroscience Graduate Program, University of Cincinnati. Thesis Advisor: Dr. Kim Seroogy 2007
More informationFirst described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"
Parkinson's Disease First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy" Parkinson s disease (PD) is a neurological disorder characterized by a progressive
More informationAnatomy of the basal ganglia. Dana Cohen Gonda Brain Research Center, room 410
Anatomy of the basal ganglia Dana Cohen Gonda Brain Research Center, room 410 danacoh@gmail.com The basal ganglia The nuclei form a small minority of the brain s neuronal population. Little is known about
More informationVariant Brain-Derived Neurotrophic Factor (Val66Met) Alters Adult Olfactory Bulb Neurogenesis and Spontaneous Olfactory Discrimination
The Journal of Neuroscience, March 5, 2008 28(10):2383 2393 2383 Cellular/Molecular Variant Brain-Derived Neurotrophic Factor (Val66Met) Alters Adult Olfactory Bulb Neurogenesis and Spontaneous Olfactory
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationNNZ-2566 in Rett Syndrome and Autism Spectrum Disorders Role and Update
NNZ-2566 in Rett Syndrome and Autism Spectrum Disorders Role and Update 1 Overview The natural growth factor IGF-1 is broken down in the body to IGF-1[1-3] NNZ-2566 is an analogue of IGF-1[1-3] developed
More informationDown regulation of the HCN2 channel in rat models of Parkinson s disease
Down regulation of the HCN2 channel in rat models of Parkinson s disease Abstract The basal ganglia is a key control centre involved with the regulation of movement. It is therefore a primary interest
More informationAdverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology
Adverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology Marcel Leist In Vitro Toxicology and Biomedicine Doerenkamp-Zbinden Chair, University of Konstanz, Germany
More informationGenetic mouse models of Huntington s and Parkinson s diseases: illuminating but imperfect
Review TRENDS in Neurosciences Vol.27 No.11 November 2004 Genetic mouse models of Huntington s and Parkinson s diseases: illuminating but imperfect Michael S. Levine 1, Carlos Cepeda 1, Miriam A. Hickey
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationDeep Brain Stimulation Surgery for Parkinson s Disease
Deep Brain Stimulation Surgery for Parkinson s Disease Demystifying Medicine 24 January 2012 Kareem A. Zaghloul, MD, PhD Staff Physician, Surgical Neurology Branch NINDS Surgery for Parkinson s Disease
More informationUSING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research
USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE The Michael J. Fox Foundation for Parkinson s Research MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission We are
More informationWELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW
WELCOME Parkinson s 101 for the Newly Diagnosed Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW Parkinson s Disease 101 Presenter for Today Cari Friedman, LCSW Patient and Family Service
More informationStudy of Verbal Working Memory in Patients with Parkinson s Disease
Study of Verbal Working Memory in Patients with Parkinson s Disease Gilbert, Belleville, Bherer, & Chouinard, 2005 presented by Jonathan Reinharth May 2, 2005 Parkinson s Disease Symptoms: resting tremors,
More informationThe Role of DOPAL in Parkinson s Disease. Karenee Demery. Copyright May, 2015, Karenee Demery and Koni Stone
The Role of DOPAL in Parkinson s Disease Karenee Demery Copyright May, 2015, Karenee Demery and Koni Stone Parkinson s disease is an incurable, neurodegenerative disease. The cause is still not fully understood.
More informationExercising Our Minds: Effects of Exercise on Brain Structure & Function
Public Lecture Exercising Our Minds: Effects of Exercise on Brain Structure & Function Dr. Brian R. Christie Division of Medical Sciences, University of Victoria Cellular and Physiological Sciences, UBC
More informationPHARMACOLOGICAL RESCUE OF PARKINSON S DISEASE SYMPTOMS. A Thesis. Presented to. The College of Arts and Sciences. Ohio University
1 PHARMACOLOGICAL RESCUE OF PARKINSON S DISEASE SYMPTOMS WITH DROSOPHILA LARVAE A Thesis Presented to The College of Arts and Sciences Ohio University In Partial Fulfillment of the Requirements for Graduation
More information